On Sunday, 25 October, 2020 the Federal Health Minister, the Hon Greg Hunt MP announced the listing of siponimod (Mayzent) for the treatment of secondary progressive MS (SPMS) on the Pharmaceutical Benefits Scheme (PBS), from 1 November, 2020.
The Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing of siponimod (Mayzent®) for patients with SPMS who are ambulant (with or without support).
This PBS listing was recommended by the independent expert PBAC and is the first time in Australia that a medicine has been listed on the PBS specifically for the treatment of SPMS.
People living with SPMS should discuss any potential treatments with their neurologist or MS nurse.
Please consult your neurologist to see if siponimod (Mayzent®) is the right treatment for you. Decisions about treatments, taking into consideration the potential benefits and side effects for your individual circumstance, should be made in careful consultation with your treating healthcare team.